Gut Microbiome Profiling in Advanced NSCLC Patients Undergoing Dual Immune Checkpoint Blockade Therapy
This project involves gut microbiome profiling in advanced non-small cell lung cancer (NSCLC) patients undergoing dual immune checkpoint blockade therapy with ipilimumab and nivolumab. Fecal samples were collected prior to therapy, and 16S rRNA gene sequencing was performed to analyze microbial diversity, composition, and metabolic pathways. This research highlights the role of the gut microbiome in immunotherapy and its potential as a biomarker for personalized medicine.